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ABSTRACT
Introduction The prevalence of at- risk drinking is 
far higher among those in contact with the criminal 
justice system (73%) than the general population (35%). 
However, there is little evidence on the effectiveness 
of alcohol brief interventions (ABIs) in reducing risky 
drinking among those in the criminal justice system, 
including the prison system and, in particular, those on 
remand. Building on earlier work, A two- arm parallel 
group individually randomised Prison Pilot study of a 
male Remand Alcohol Intervention for Self- efficacy 
Enhancement (APPRAISE) is a pilot study designed to 
assess the feasibility and acceptability of an ABI, delivered 
to male prisoners on remand. The findings of APPRAISE 
should provide the information required to design a future 
definitive randomised controlled trial (RCT).
Methods and analysis APPRAISE will use mixed 
methods, with two linked phases, across two prisons in 
the UK, recruiting 180 adult men on remand: 90 from 
Scotland and 90 from England. Phase I will involve a two- 
arm, parallel- group, individually randomised pilot study. 
The pilot evaluation will provide data on the likely impact 
of A two- arm parallel group individually randomised 
Prison Pilot study of a male Remand Alcohol Intervention 
for Self- efficacy Enhancement (APPRAISE), which will be 
used to inform a future definitive multicentre RCT. Phase 
II will be a process evaluation assessing how the ABI has 
been implemented to explore the change mechanisms 
underpinning the ABI (figure 1) and to assess the context 
within which the ABI is delivered.
Ethics and dissemination The APPRAISE protocol 
has been approved by the East of Scotland Research 
Ethics Committee (19/ES/0068), National Offender 
Management System (2019-240), Health Board Research 
and Development (2019/0268), Scottish Prison Service 
research and ethics committee, and by the University of 
Edinburgh’s internal ethics department. The findings will 
be disseminated via peer- reviewed journal publications, 
presentations at local, national and international 
conferences, infographics and shared with relevant 
stakeholders through meetings and events.
Trial registration number ISRCTN27417180.
INTRODUCTION
Background/Rationale
The prevalence of at- risk drinking, which 
is defined as drinking at levels that harm a 
person’s health, is far higher among those 
within the criminal justice system (73%)1–5 
than the general population (35%).6 In the 
United Kingdom (UK), between 51% and 
83% of incarcerated people are classified 
as risky drinkers,7 and for those on remand 
in prison, the prevalence is between 62% 
and 68%.5 Furthermore, alcohol depen-
dence among those incarcerated (43%) is 10 
times higher than the general population.5 
Strengths and limitations of this study
 ► This study provides a unique opportunity to evalu-
ate the feasibility of conducting trial- based research 
with men on remand in prison, a frequently under- 
represented group in research.
 ► A significant strength is that it will assess the fea-
sibility and acceptability of the alcohol brief inter-
vention from multiple perspectives, including men 
on remand, prison- based intervention teams and 
additional stakeholder groups.
 ► It will provide an opportunity to identify the opera-
tional criteria necessary for a future definitive ran-
domised controlled trial.
 ► The unique context provides challenges for re-
search, and the prisons’ day- to- day running will 
influence research activities.
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The impacts of risky drinking are significant, resulting 
in significant health, economic and social burden on 
individuals, families and society as a whole.8 Addressing 
alcohol harm in prisons, at what can be considered 
a ‘teachable moment’, could reduce the risk of reof-
fending, reduce costs to society and help address health 
inequalities.9
There is currently robust evidence from systematic 
reviews and meta- analyses, indicating that alcohol brief 
interventions (ABIs) are effective in reducing alcohol 
consumption among at- risk drinkers in healthcare 
settings.8 9 However, there is little evidence of the effec-
tiveness of ABIs in reducing risky drinking among those 
incarcerated, particularly those on remand,10 11 despite 
there being evidence in the UK that ABIs can reduce 
recidivism.12
In addition, ABIs have been shown to reduce recidi-
vism within the probation setting.13 Our systematic review 
of the efficacy of psychosocial alcohol interventions for 
incarcerated people10 found that interventions within 
prison have the potential to impact alcohol use positively; 
however, because of small numbers and different outcome 
measures, it was not possible to conduct a meta- analysis or 
generalise findings. Notably, none of the studies focused 
on men on remand, with remand referring to individ-
uals who are unconvicted or convicted and unsentenced, 
held in custody awaiting trial and/or sentencing. The 
intervention in this proposed study builds on previous 
research exploring the theoretical validity of a self- efficacy 
enhancing ABI.14 15 This intervention was initially tested 
within a pilot cluster randomised controlled trial (RCT), 
in a general hospital setting, and provided evidence of a 
potential effect.15
In the recently completed Alcohol Brief Interventions 
(ABIs) for male remand prisoners: an Medical Research 
Council (MRC) complex intervention framework devel-
opment and feasibility study (PRISM- A), an ABI was 
developed and refined within the prison setting, working 
with men on remand to include a synthesis of their views, 
with reviews of the evidence base and theoretical under-
pinnings.16 17 The findings also showed a high prevalence 
of at- risk drinking, with 82% of participants scoring ≥8 
on the Alcohol Use Disorders Test (AUDIT).17 This is 
comparable with other findings in the prison system 
in the UK1–5 but is more than three times higher than 
primary care settings.6 The study results indicated high 
levels of willingness of both staff and participants to 
engage with the intervention. Also, support was shown for 
an extended intervention, which helped men on remand 
to develop skills and strategies that would be useful for 
liberation. The feedback regarding frequency and inten-
sity of contact identified a preference for more than one 
session, including additional community- based sessions, 
to allow participants to put their skills into practice when 
alcohol is more widely available. Based on learning from 
interviews within the PRISM- A study, the intervention 
for the APPRAISE pilot study includes three post- release 
booster sessions.
However, there is limited evidence around the optimum 
timing of delivery, recommended length, content, imple-
mentation and economic benefit of an ABI in the prison 
setting. Furthermore, there are weaknesses within the 
current evidence base, with interventions not having 
theoretical underpinnings.11 18 This risks an intervention 
being used with a weak theoretical base, poorly specified 
‘active’ ingredients and less likely to deliver the desired 
outcomes.
Following on from the positive results from the PRISM- A 
study, the MRC framework suggests the next step is to 
conduct a pilot study.19 Therefore, the APPRAISE pilot 
trial has been proposed to strengthen the evidence 
around ABIs targeted at male remand prisoners. It will 
seek to assess the feasibility and acceptability of the ABI, 
in comparison to usual care, and it will explore the poten-
tial effectiveness of the key parameters. It will also aim to 
provide the information required to be able to design a 
definitive RCT.
Aim
The APPRAISE study aims to undertake a two- arm, 
parallel- group, individually randomised, pilot study of 
a self- efficacy enhancing psychosocial alcohol interven-
tion, for men on remand, in prison. If this pilot study 
is successful, it will provide the evidence to support the 
design of a future multicentre RCT.
The specific study objectives are as follows.
Objective 1: to pilot the study measures and evaluation methods 
to assess the feasibility of conducting a multicentre, pragmatic, 
parallel-group, RCT
1a. Is it feasible to conduct a future multicentre RCT of 
a self- efficacy enhancing psychosocial ABI for men on 
remand?
1b. Can we obtain reasonable estimates of the parame-
ters necessary to inform the design and sample size calcu-
lation for an RCT, including SD of potential continuous 
primary outcomes and estimates of recruitment, reten-
tion and follow- up rates?
1c. Can we determine, based on rates of missing data, 
whether the questionnaires are appropriate for the target 
population?
1d. Can we collect economic data needed for an RCT?
1e. Can we access recidivism (as measured by ‘proven’ 
reconviction rates20 data derived from the Police National 
Computer (PNC) for participants)?
1f. Can we access health data from National Health 
Service (NHS) data sources for participants?
Objective 2: to assess intervention fidelity
2a. What proportion of the interventions are delivered as 
per protocol?
2b. Is there any evidence of contamination between 
the two arms and/or between workers delivering the 
intervention?
2c. To what extent does the intervention change process 
variables consistent with the underpinning theory?
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Objective 3: to qualitatively explore the feasibility and acceptability 
of the intervention and study measures to staff and participants on 
remand and on liberation
3. How acceptable are the trial and intervention proce-
dures (including context and any barriers and facilita-
tors) to the key stakeholders: men on remand in prison 
and on liberation; prison staff (including healthcare 
staff); commissioners; policy makers and third sector 
partners?
Objective 4: to assess whether operational progression criteria 
for conducting a future definitive RCT are met across trial 
arms and study sites and if so, develop a protocol for an RCT. 
Operational progression criterion are based on previous research 
results3
4a. Do the two prisons invited to the study agree to take part?
4b. Based on knowledge from previous data, do at least 90 
eligible participants consent to take part and be randomised?
4c. Do at least 70% of participants allocated to the inter-
vention condition go on to receive at least one intervention 
session?
4d. Do at least 60% of participants take part in the follow- up 
assessments at 12 months across trial arms and study sites?
METHODS AND ANALYSIS
Study design
The study aligns to the MRC framework19 using mixed 
methods within two linked phases conducted across two sites.
Phase I will involve a two- arm, parallel- group, individ-
ually randomised pilot study (Objectives 1 and 4). The 
pilot evaluation will provide data on feasibility and an 
assessment on the likely impact of the ABI to inform the 
feasibility and design of a future RCT.
Phase II will comprise a process evaluation (Objec-
tives 2 and 3), drawing on the MRC process evaluation 
framework to guide the planning and design of the eval-
uation.21 The aim of the process evaluation is: to assess 
how the ABI is implemented; to undertake a preliminary 
exploration of the change mechanisms underpinning the 
intervention (figure 1), and assess the delivery context of 
the ABI.
Participants and setting
Identification of study participants
A suitable process of participant identification was 
established and found to be successful in the PRISM- A 
study.16 17 The prison induction team (consisting of 
Figure 1 APPRAISE logic model.
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prison officers and peer prisoners) will provide poten-
tial participants with a verbal account of the study and a 
Participant Information Sheet (PIS) during their prison 
induction. Researchers will liaise with relevant prison offi-
cers each week to identify potential participants. Poten-
tial participants will be contacted via prison staff; those 
who are willing will meet with the researcher in an area 
of the prison where they can discuss issues in private, 
without risk of being overheard, and without risk to the 
interviewer or disruption to the running of the prison. 
The researcher will review the PIS with the participant, 
provide a written and verbal description of APPRAISE, 
answer any questions and invite him to consider partic-
ipating. The researcher will then obtain written consent 
from willing participants. Those who do not wish to partic-
ipate will receive no further interaction with the research 
staff. Data collection began on 1 December 2019 and will 
finish on 31 August 2021.
Sample size
A total of 180 adult men (18 years and over) on remand 
will be recruited from two sites: one within the Scot-
tish Prison Service (SPS) (n=90); and the second from 
Her Majesty’s Prison and Probation Service (HMPS) in 
England (n=90). These sites were purposively selected 
following PRISM- A, as they offer geographical, socioeco-
nomic and ethnic diversity, along with differing proce-
dures and structures.16 Both prisons provide alcohol 
services via external agencies who engage with people 
in custody and following release. Prisons have varying 
induction procedures, communication mechanisms and 
processes, and available, secure space to engage partic-
ipants. Understanding the different approaches and 
dynamics will be important when designing a future RCT.
The target population is men on remand in prison, 
who have been in prison for 3 months or less. The average 
time on remand is approximately 9 weeks in England22 
and 4 weeks in Scotland.23 We estimate that approxi-
mately 50% of participants will be released, while the rest 
will remain incarcerated; leaving 45 participants per study 
arm (90 in total) across the two sites.
This sample size was calculated to take account of the 
following factors24:
1. It will enable calculations of two- sided 95% CIs around 
proportions recruited, released and dropout in each 
study arm with half- widths of less than 0.15.
2. It exceeds the 30 per group recommendation of Lan-
caster et al25 and 35 participants per group recommen-
dation of Teare et al26 for estimating key unknown de-
sign parameters, for example, SD with sufficient preci-
sion with a continuous primary outcome.
3. It will ensure that within each arm, across each site, 
we satisfy the minimum 12 per group ‘rule of thumb’ 
outlined by Julious27 for pilot trials.
Participant eligibility criteria
The following criteria were used in PRISM- A and were 
found to be appropriate.
Inclusion criteria
Participants will be included in APPRAISE if they meet 
the following inclusion criteria:
 ► Informed consent given.
 ► Men aged 18 years or over.
 ► Have been in prison for 3 months or less on the 
current charge.
 ► Score 8 or more on the AUDIT.28
 ► Detained in either of the study sites within the SPS or 
HMPS.
Exclusion criteria
Participants will be excluded from APPRAISE if they meet 
any of the following criteria:
 ► Previously recruited to APPRAISE.
 ► Unable to give informed consent or deemed incompe-
tent/unable to make an informed decision regarding 
consent.
 ► Identified as a risk to self and/or others by prison 
staff.
 ► Judged to be under the influence of an illicit substance 
by prison or research staff.
 ► Currently taking disulfiram (frequently referred to as 
Antabuse).
 ► On a segregative rule (under prison rules).
 ► Not able to understand the documents (English 
language) or agree to the researcher aiding their 
understanding.
Informed consent
All participants will be required to provide informed 
consent before taking part; their decision will be entirely 
voluntary and based on a clear understanding of what 
is involved. To ensure this, all participants will receive 
a verbal explanation of the study, in addition to a PIS. 
The verbal explanation will be given by the researcher 
and will cover all elements in the PIS and the consent 
form. Each willing participant will sign a consent form 
to ensure that informed consent has been obtained. 
Each participant will receive a copy of the form, and 
a copy will be filed in the Investigator Site File (ISF). 
All participants will be given sufficient time to consider 
the information provided, ask questions and clarify 
anything they do not understand. Participants will be 
reassured that they can withdraw their consent at any 
time, without loss of benefits to which they otherwise 
would be entitled.
Ethics and dissemination
The APPRAISE protocol has been approved by the East 
of Scotland Research Ethics Committee (19/ES/0068), 
National Offender Management System (2019–240), 
Health Board Research and Development (2019/0268), 
Scottish Prison Service (SPS) research and ethics 
committee and by the University of Edinburgh’s internal 
ethics department. The findings will be disseminated via 
peer- reviewed journal publications, presentations at local, 
national and international conferences, infographics and 
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shared with relevant stakeholders through meetings and 
events.
The APPRAISE intervention
The ABI has four sessions to be offered to all participants 
in the intervention arm. It will be delivered by existing 
staff at the voluntary sector organisation (VSO) who 
are currently engaged in alcohol service delivery in the 
prison and community setting. The ABI comprises nine 
elements (see tables 1 and 2) and will be delivered in four 
steps: Step 1 is 1×40 min, face- to- face session, covering 
nine elements, delivered by a trained (VSO) staff member 
within the prison. Steps 2, 3 and 4 are 20- minute sessions, 
by phone, on or as close to day 3, 7 and 21 post- liberation. 
Exact days will be recorded to inform the process evalu-
ation. The post- liberation sessions will include elements 
1 (preliminary discussion), 5 (situation- appraisal), 
6 (goal setting), 7 (relapse), 8 (self- evaluation/self- 
reinforcement) and 9 (culmination).
Self- efficacy derives from Social Cognitive Theory and 
has been identified as an important determinant of health 
behaviour and health behaviour change.29 The four 
primary sources of self- efficacy information (that can be 
targeted through interventions) are mastery experience, 
vicarious experience, verbal persuasion and physiological 
state.14 15 29 The ABI is designed to increase self- efficacy—
through the development of self- regulatory skills, self- 
management and self- belief, thus enabling an individual 
to address their alcohol consumption. Liberation then 
offers participants the ability to develop and build on 
these skills and self- belief through success and mastery, 
with their efforts leading to the adoption and mainte-
nance of reduced alcohol consumption.14 29 Reducing 
alcohol consumption can provide a sense of achievement 
and success, with the overall effects of such an interven-
tion a likely increase in the men’s level of self- efficacy.14
Staff training
Two members of VSO staff at each site will be trained 
to deliver the ABI to participants (intervention), and 
the remaining staff will have no training (control). 
This method seeks to minimise contamination and has 
been used in other similar studies.30 31 The possibility of 
residual contamination and the practicality of allocating 
staff according to randomisation will be explored within 
the process evaluation to inform the future RCT. Weekly 
debriefs with interventionists delivering the APPRAISE 
ABI will also enable the exploration of possible 
contamination.
Intervention delivery
The ABI has four sessions to be offered to all participants 
in the intervention arm. Understanding what has been 
delivered and how is a key component of understanding 
the ABI implementation.32 33 As part of the process eval-
uation to assess implementation, measures of fidelity 
(quality) and dose (quantity) will be recorded and anal-
ysed. To capture fidelity, we will digitally audio record 
20% of intervention sessions and code these, using the 
Behaviour Change Counselling Index (BECCI),34 to assess 
the extent to which the essential theoretical elements of 
the ABI were delivered as intended. To capture dose, 
quantitative data from participant study records and logs 
will be obtained to assess the proportion of interventions 
offered and delivered successfully. The number of inter-
vention sessions offered, delivered and the length of each 
session will be recorded as will reasons for any unsuc-
cessful delivery. Interviews with all implementers and 32 
purposively selected participants will also be conducted at 
each site to identify how acceptable the trial intervention 
and procedures were.
Control condition (care as usual)
The control condition will include participants receiving 
care as they usually would, within the existing service 
provision. What constitutes care as usual will vary between 
participants as some participants may access no support. 
In contrast, others may attend individual or group- based 
support sessions with VSO and/or other providers while 
in prison or their local communities. It should be noted 
that participants in the intervention condition will also 
have access to care as usual services. Service utilisation 
will be recorded for all participants.
Table 1 Outline of APPRAISE intervention
Element
Elements of 
intervention14
Enhancing 
self- efficacy
Delivery method 
and location
1 Preliminary 
discussion
Verbal 
persuasion
Face to face (P)
Mobile phone (L)
2 Acquiring 
and providing 
information
Verbal 
persuasion
Face to face (P)
3 Self- monitoring Verbal 
persuasion
Face to face (P)
4 Increasing 
awareness
Physiological 
state
Face to face (P)
5 Situation- 
appraisal and 
appropriate 
coping 
strategies*
Vicarious 
experience
Face to face (P)
Mobile phone (L)
6 Goal setting* Verbal 
persuasion
Face to face (P)
Mobile phone (L)
7 Relapse* Performance 
attainment
Face to face (P)
Mobile phone (L)
8 Self- evaluation/
self- 
reinforcement*
Performance 
attainment
Face to face (P)
Mobile phone (L)
9 Culmination Performance 
attainment
Face to face and 
mobile phone (L)
*Elements 5–8 highly rated by participants in the feasibility study 
(PRISM- A) and will form key focus of intervention delivery by 
mobile phone on liberation.
L, liberation; P, prison.
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Data collection
Baseline assessment
Following appropriate consent procedures, baseline (TP0) 
data will be collected via researcher- led completion of ques-
tionnaires, and this will take approximately 30 min. Immedi-
ately after, participants will be randomised to the control or 
intervention arm and informed of their allocation. Partici-
pants randomised to the intervention arm will be provided 
with a face- to- face appointment to meet with their inter-
ventionist. This is the process used by the current providers 
((VSO)when engaging with individuals in the prison setting. 
The three telephone sessions will be delivered following 
release from prison by one of the trained interventionists. 
In addition to the outcome measures (described below), 
data on age, gender, marital status, educational status and 
contact details will be collected.
Blinding
Due to restrictions regarding electronic equipment and 
mobile phone use by researchers while in prison, a rando-
misation system, such as an interactive voice response 
telephone system or one accessed over the web, cannot 
be used. Allocation will be conducted at participant level 
using random permuted blocks of variable size3 5 6 strat-
ified by site using sealed envelopes, based on a prede-
termined random number allocation carried out by 
Edinburgh Clinical Trials Unit (ECTU).27 35
Researchers will not be involved in delivering the active 
and control interventions but will be aware of the study 
allocation of participants as the trial progresses. Allo-
cation concealment will be used whereby neither the 
person delivering the interventions nor the participant 
will be aware of the study allocation until they are irre-
vocably entered into the trial. Both the trial statistician 
(RP) and health economist (JB) will be blinded to group 
allocation and will only have details of study participants 
by study number.
Follow-up
Follow- up assessments will be conducted at 6 (TP1) and 
12 months (TP2) post recruitment. The original aim was 
Table 2 APPRAISE intervention elements
Element 1: Preliminary discussion Opening strategies
  Introduction to APPRAISE study   
  Introduction to APPRAISE 
intervention
  
  Consent, confidentiality, 
engagement rules, trust
  
Element 2: Acquiring and providing 
information
Feedback on AUDIT 
score
  Establish perception of impact of 
alcohol on health and life
  
  Standard units of alcohol   
  Recommended drinking levels   
  Alcohol- related health problems   
  Legal drink/drive limit   
  Tips on reducing consumption   
  Where to obtain information/support 
(prison and liberation)
  
Element 3: Self- monitoring Diary card—when, 
where, whom, type of 
drink, why
Element 4: Increasing awareness Balance sheet—pros 
and cons of drinking
  Physiological sensations identified   
  Alternative appraisal of somatic 
sensations identified
  
  Strategies to reduce   
Element 5: Situation- appraisal and 
appropriate coping strategies
High- risk situations and 
antecedents of over- 
drinking identified
  Alternative coping strategies 
identified
  
  Coping strategies verbalised by 
participant
  
  Praise provided   
  Strategies developed further 
through coproduction
  
  Strategies modelled by 
interventionist
  
  Participant verbalises strategies and 
visualises them
  
  Plan for exposure/avoidance to 
low- risk situations and high- risk 
situations
  
  General control strategies: reduction 
in rate of drinking, sipping, low- 
alcohol content and alternating 
between soft or low- alcohol drinks
  
Element 6: Goal setting Setting realistic 
subgoals (short term)
  Facilitating success and increasing 
motivation
  
Element 7: Relapse What happens if you 
relapse
  What caused the relapse?   
Continued
  How do I understand relapse?   
Element 8: Self- evaluation and self- 
reinforcement
Using my alcohol diary 
as a means of self- 
evaluation and self- 
reinforcement
  Self- congratulations and rewarding 
my success
  
  What do I attribute my success to?   
Element 9: Culmination Reflections and 
conclusions
  Plans and goals reiterated and 
confirmed
  
AUDIT, Alcohol Use Disorders Test.
Table 2 Continued
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for these to be conducted by the researcher either in 
person or by telephone. In light of COVID-19 restrictions, 
follow- up assessments have also been adapted to enable 
self- completion using hard copies or electronic versions. 
Where participants are identified as being incarcerated 
at follow- up, arrangements with the relevant prison will 
be made to undertake the follow- up. Attempts to contact 
participants will be multifaceted, including telephone 
calls, text messages and emails, based on participants’ 
preferred method of contact, at varying times and days 
of the week. We will record the number of participants 
invited to participate; responded; were eligible; recruited; 
transferred; subsequently sentenced; liberated, and lost 
to follow- up. The number who returned to prison during 
the 12 months and who completed the trial will also be 
recorded.
Outcomes
Primary outcome measure
The proposed primary outcome measure is alcohol 
consumed, in units where one unit equals 8 g or 10 mL of 
ethanol, per week will be derived from the frequency and 
quantity of alcohol consumption questions in the extended 
version of AUDIT using a formula developed and employed 
in a number of RCTs of interventions for alcohol consump-
tion.36 37 A score of 8+ is referred to as a ‘positive screen’ 
and indicates drinking at hazardous (score of 8–15), 
harmful (score of 16–19) or probable dependent level 
(score of 20+). A score of 8 or more out of a possible 40 on 
the AUDIT has an established sensitivity of 92% and speci-
ficity of 94%28 to detect those at risk of harm from alcohol 
use. The AUDIT will be administered at TP0, TP1 and TP2.
Self-report secondary outcomes measures
Secondary outcome measures will be completed at TP0, 
TP1 and TP2.
The Warwick- Edinburgh Mental Well- being scale 
(WEMWBS) will be used to assess mental well- being.38 
This tool uses a 5- point Likert scale, which gives a score 
of 1 to 5 per question, giving a minimum score of 14 and 
maximum score of 70. A higher WEMWBS score indicates 
a higher level of mental well- being.38
Readiness to change will be measured using the Read-
iness to Change Ruler, which measures readiness to 
change drinking behaviour.7
Self- reported alcohol self- efficacy will be measured 
using the Drinking Refusal Self- Efficacy Questionnaire—
Revised (DRSEQ- R)39 and alcohol expectancy, using the 
Negative Alcohol Expectancy Questionnaire (NAEQ).40
The EuroQol five- dimensional five- level (EQ- 5D- 5L) 
will be used to measure health- related quality of life and is 
being scoped for potential future use to generate quality- 
adjusted life years (QALY).41 A bespoke public sector 
service use questionnaire will be adapted based on the 
Economic Form 9042 to determine public sector costs in 
the domains of health and social care, criminal justice 
system, unemployment and welfare.
Other secondary outcome measures
Attempts will be made to access data from the PNC 
to collect individual- level data on recidivism rates as 
measured by ‘proven’ reconviction rates20 over 12 
months, since TP0. The number of participants incarcer-
ated at TP1 and TP2 will also be recorded.
Individual- level data relating to health and social care 
use will also be sought. If access is possible, data derived 
from Community Health Index (CHI)/NHS number at 
TP3 will be used to validate the bespoke public sector 
service use questionnaire. Furthermore, data will be 
collected on the time spent by researchers and practi-
tioners on APPRAISE to inform the resources needed for 
a definitive RCT.
Mechanisms of impact
An intervention logic model (figure 1) informed by Social 
Cognitive Theory has been developed. The underlying 
causal mechanisms will be examined to provide increased 
understanding of how the intervention influences change 
through the quantitative assessment of key behavioural 
markers (mediators) of change, that is, self- reported self- 
efficacy, using the DRSEQ- R39 and alcohol expectancy, 
using the NAEQ.40 These behavioural markers of change 
will be recorded at TP0, TP1 and TP2. An exploratory 
prognostic analysis will be undertaken to explore the 
nature of change within these domains and their relation-
ship to the primary outcome. The relationship between 
alcohol consumption, receipt of the intervention and 
reoffending will also be assessed. In addition, we will be 
interviewing 32 men who took part in the study (16 at 
each site), 8 intervention staff from CGL and 10 addi-
tional stakeholders. The qualitative exploration of partic-
ipant responses to and interactions with the intervention 
will be undertaken to identify unanticipated pathways 
and consequences at 12 months of follow- up.
Data analysis
The progress of participants through the APPRAISE pilot 
trial will be presented in accordance with the CONSORT 
(Consolidated Standards of Reporting Trials) guidelines43 
to allow descriptions of key parameters required for a future 
RCT; eligibility rates, consent, adherence, retention at 
follow- up and data completeness of outcome measures.
The statistical analyses will be primarily descriptive, 
providing an estimate of the proportion of those eligible, 
consenting, adhering to the intervention and retention 
rates at 6 and 12 months. These parameters will inform the 
power calculations for a future RCT and confirm or identify 
the need for modifications in relation to other aspects of the 
trial design, particularly the acceptability of study processes 
and outcome measures to participants and staff. Data about 
the flow of participants through the APPRAISE pilot trial 
will include numbers screened, the prevalence of the target 
condition, numbers providing contact details, numbers 
eligible and willing to consent and numbers followed up 
successfully at TP1 and TP2. In addition, data completeness 
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for each of the instruments and any potential bias in the 
follow- up data will be ascertained.
Analysis of the primary outcome will also provide estimates 
of the variance within and between groups for exploration of 
sample size calculations for a definitive RCT. Furthermore, 
we will calculate the variance of all primary and secondary 
outcome measures within groups to explore their utility in 
a definitive study. If access to PNC data is possible, proven 
reconviction rates will be measured by the number of offences 
committed by each treated participant against the number 
committed in the comparison group. Time- to- event analysis 
will also explore differences in offending patterns.
Calculation of between trial- arm differences (with 95% 
CIs) will indicate the likely effect sizes that will be observed in 
a future definitive trial.
For the primary outcome analysis, the mean difference 
(with 95% CI) in alcohol units consumed between the two 
randomisation groups will be calculated, both overall and 
stratified by site. A complete case analysis will be used, but 
a sensitivity analysis will also be incorporated to explore the 
effects of missing data. This will involve using multiple impu-
tations for the primary outcome in a supplementary analysis, 
provided that the valid sample size is sufficient to support 
this. In addition, we will add and subtract one- unit difference 
(alcohol units) to the missing data as part of a sensitivity anal-
ysis to explore how the 95% CIs change depending on our 
assumptions about the missing data (bearing in mind that 
the imputed data cannot be less than zero). This is similar to 
the sensitivity analysis method suggested in White et al (2011) 
which involves determining how large an amount can ‘be added 
to or subtracted from the imputed data without changing the clinical 
interpretation of the trial’. We will adopt a similar approach to 
determine how sensitive the conclusions of the APPRAISE 
pilot trial (and the decision about whether to proceed with 
an RCT) are to our assumptions about missing data.
A statistical analysis plan will be written and finalised prior 
to analysis.
Health economic evaluation
Full details of all health economic analyses will be speci-
fied in a health economic analysis plan, authored by the 
trial health economist(s), and signed off by the Principal 
Investigator prior to analysis.
In brief, this will scope the feasibility of conducting a 
future health economic evaluation alongside any future 
trial. A bespoke survey of public sector service use will 
be adapted from the Economic Form 9042 and tested in 
the patient population. We will also scope the potential 
for using the EQ- 5D- 5L relative to other health outcome 
measures being used in the trial. The rates of response 
and completeness of questionnaires will be reported in 
each case. A dry run costing/QALY generation exer-
cise will be undertaken to identify any practical issues in 
using these instruments. The dry run costing exercise will 
include a detailed scoping of the cost elements relating 
directly to the introduction and running of the interven-
tion through consultation with key staff involved in the 
implementation. Finally, the potential for longer- term 
modelling of outcomes will be scoped through consulta-
tion with experts and non- systematic searches of the liter-
ature for similar work or anticipated parameters. These 
will form the basis for a short report to aid in developing 
a future protocol for a follow- up trial.
Additional analyses
All interview data will be transcribed and thematic anal-
ysis undertaken in order to fulfil Objectives 1d, 2c and 
3a. Braun and Clarke’s thematic analysis framework will 
guide this, as it is congruent with the study’s theoretical 
perspective.44 To facilitate an understanding of each 
stakeholder group’s perspective, the data will initially be 
analysed within group. The rationale for undertaking the 
analysis within each group is to enable the targeting of 
remedial actions within a future RCT. Themes running 
across the data, in relation to each question, will then 
be collated, providing a multiperspective understanding 
of the stakeholder experience for each element of the 
intervention/study.
The qualitative analysis will provide evidence to verify 
the feasibility and acceptability of the ABI to participants, 
specifically elements 5–8. It will also inform the process 
evaluation in phase II to better understand and explain 
the social processes of the intervention, through the lens of 
implementation theory, Normalisation Process Theory.45–48
Monitoring
An APPRAISE Trial Steering Committee (TSC) has been 
set up to monitor the implementation, to provide an 
independent assessment of the data analysis and to deter-
mine if a future trial is merited.
The TSC has the following objectives:
 ► Provide supervision of the trial on behalf of the 
sponsor and funder and ensure it is conducted to 
rigorous standards.
 ► Monitor the ongoing progress and adherence to 
protocol.
 ► Consider new information of relevance to the research 
question.
 ► Provide advice, through the chair, to the chief investi-
gator and funder on all appropriate aspects.
 ► Provide evidence to support extension requests.
In addition to the TSC, the chair plus three TSC 
members (specialising in health economics, statistics, 
and qualitative methodology and analysis) have formed a 
subcommittee responsible for data monitoring and ethics 
(DMEC).
The DMEC subcommittee has the following objectives:
 ► To monitor the data and recommend the TSC on 
whether there are any ethical or safety reasons why 
the trial should not continue.
 ► To ensure that the safety, rights and well- being of 
participants remain paramount.
The subcommittee will also consider the need for any 
interim analysis and are the only body who, if necessary, 
will have access to the unblinded data.
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Data management
Data from both study sites will be anonymised, and individ-
uals’ data will only be identifiable by their unique screening 
number. All of the hard copy data from the England site will 
be sent to the coordinating site, The University of Edinburgh, 
by secure courier, where all of the data will then be stored in a 
locked filing cabinet, with restricted access. Personal or sensi-
tive data will be transported separately between sites securely, 
using password- protected files. No personal data will be trans-
ferred outside the UK, or stored or collected on computer 
servers outside the UK.
Audio files will be uploaded securely to a password- 
protected site by the researchers, where the approved tran-
scription company will be able to access the files. Transcribed 
files will be returned to the researchers using the same secure 
platform and downloaded and stored securely in folders on 
the University of Edinburgh’s password- protected server. 
Following a quality check to ensure the transcribed files’ 
accuracy, all audio recordings will be securely destroyed.
Confidentiality and data protection
All study staff will comply with the requirements of the appro-
priate data protection legislation (including the General Data 
Protection Regulation and Data Protection Act) concerning 
the collection, storage, processing and disclosure of personal 
information. All evaluation forms, reports and other records 
will maintain participant confidentiality and only be iden-
tifiable via a unique participant identification number. All 
written records will be kept in a secure storage, and computers 
used to collate the data will be password protected. Published 
results will not contain any personal data to ensure that indi-
viduals cannot be identified. Personal data will be stored for 
24 months after the study completion, and following this will 
be securely destroyed.
Ethical considerations
Ethical approval has been obtained from the East of Scot-
land NHS Research Ethics Committee, the Scottish Prisons 
Service Research Ethics Committee, Her Majesty’s Prison and 
Probation Service and the University of Edinburgh School of 
Health in Social Science Research Ethics Committee.
Due to the high- risk population group, study staff will 
document any occasions where a session has had to be 
stopped due to participant distress or where the session 
is terminated because the researcher or prison staff 
identify a risk to the researcher. This information will be 
communicated to the chair of the TSC within a week of it 
occurring. In Scotland, it will be possible to identify and 
document whether participants are put on a suicide risk 
management strategy while they are in prison. This will 
be monitored and any participant put onto this strategy 
within a week of being in contact with study staff will be 
flagged and reported to the chair within 24 hours.
Dissemination
Our dissemination plan will include local, national and 
international avenues. The findings will be prepared 
for publication via open access, peer- reviewed journal 
articles. Also, the APPRAISE pilot trial findings and any 
plans for a future RCT will be presented to Health and 
Justice Teams at Scottish Government and Public Health 
England, the National Prisoner Healthcare Network 
(Scotland) and the WHO (Health in Prisons Programme 
Collaborating Centre). We will ensure participants can 
engage with research findings through infographics and 
will feedback to the participating sites. Other dissemi-
nation opportunities include presentations at meetings, 
workshops, national and international conferences, or at 
relevant organisations and events, such as Scottish Alcohol 
Research Network, Scottish Health Action on Alcohol 
Problems and Offender Health Research Network.
Patient and public involvement
Patient and public involvement has informed and influ-
enced the development of the study. Representatives have 
included those with lived experience of imprisonment and 
those involved in the delivery of alcohol support and advice 
to criminal justice populations. Their expertise has informed 
the development of study materials and will also inform the 
analysis, reporting and dissemination of the research.
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